Company: WHWK
Filing Date: 2025-01-31
Form Type: DEFM14A
Source: 0001193125-25-018470
Chunk: 403

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-01-31
Form: DEFM14A
Chunk 403
---
 FYARRO or any of our other product candidates that we may develop                                                                                                   
 in the future according to our schedule and specifications, or at all, including if our third-party contractors give greater priority to the supply of other products over our product candidates or otherwise do 
 not satisfactorily perform according to the terms of the agreements between us and them;                                                                                                                          |

| • |     | the termination or nonrenewal of arrangements or agreements by our third-party contractors at a time that is 
 costly or inconvenient for us;                                                                               |

| • |     | the breach by the third-party contractors of our agreements with them; |

| • |     | the failure of third-party contractors to comply with applicable regulatory requirements, including manufacturing 
 drug supply pursuant to strictly enforced cGMPs;                                                                  |

| • |     | the failure of the third-party contractor to manufacture FYARRO or any of our other product candidates that we 
 may develop in the future according to our specifications;                                                     |

| • |     | the mislabeling of clinical supplies, potentially resulting in the wrong dose amounts being supplied or active 
 drug or placebo not being properly identified;                                                                 |

| • |     | clinical supplies not being delivered to clinical sites on time, leading to clinical trial interruptions, or of 
 drug supplies not being distributed to commercial vendors in a timely manner, resulting in lost sales; and      |

| • |     | the misappropriation of our proprietary information, including our trade secrets and know-how. |

- 275 -

We do not have complete control over all aspects of the manufacturing process of our contract manufacturing
partners and are dependent on these contract manufacturing partners for compliance with cGMP regulations for manufacturing both active pharmaceutical ingredients (“API”) and finished drug products. To date, we have obtained drug substance
and drug product from third-party manufacturers to support preclinical and clinical testing of FYARRO. We are in the process of developing our supply chain for FYARRO, including through a new supply agreement with Fresenius Kabi. As we commercialize
FYARRO or any other product candidates we may develop in the future through development, we will consider redundant supply for the API and drug product for FYARRO and each of our product candidates that we may develop in the future to protect
against any potential supply disruptions. However, we may be unsuccessful in putting in place such framework agreements or protecting against potential supply disruptions.

Third-party manufacturers may not be able to comply with cGMP regulations or similar regulatory requirements outside of